3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Rhabdomyosarcoma
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Central Nervous System Neoplasms
1
Interventions
Specimen Handling
150
pembrolizumab
132
Magnetic Resonance Spectroscopy
120
Cyclophosphamide
118
Biopsy
106
fludarabine
90
Nivolumab
61
Carboplatin
55
Radiotherapy
49
Cisplatin
49
Gemcitabine
48
venetoclax
43
Paclitaxel
43
Cetuximab
40
fludarabine phosphate
39
Ipilimumab
36
Fluorouracil
35
atezolizumab
34
Bevacizumab
33
durvalumab
30
Radiation
30
Oxaliplatin
29
X-Rays
28
Leucovorin
28
Dexamethasone
28
Azacitidine
27
Irinotecan
26
Cytarabine
26
Radiosurgery
24
Injections
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
amino-acid, glucose, and electrolyte solution
×
90 days
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled